Nordic Nanovector In Limbo As Merger Collapses
Shareholders Reject APIM Link-Up
The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
You may also be interested in...
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.